ARCT
HealthcareArcturus Therapeutics Holdings Inc.
$6.37
+$0.12 (+1.92%)
Jan 5, 2026
Price History (1Y)
Analysis
Arcturus Therapeutics Holdings Inc. is a healthcare company in the biotechnology industry with a market capitalization of $181.00M and 174 employees. It is listed on the stock exchange under the ticker symbol ARCT. The company's financial health is marked by significant losses, with a net income (TTM) of -$66,709,000 and an EBITDA of -$75,185,000. The gross margin is -96.7%, operating margin is -96.3%, and profit margin is -68.3%. Returns on equity and assets are also negative at -27.4% and -15.0%, respectively. On the balance sheet side, Arcturus has $180.36M in cash but $25.99M in debt, resulting in a debt to equity ratio of 11.57. Arcturus' valuation metrics include a forward P/E ratio of -2.54, price to book ratio of 0.77, and price to sales ratio of 1.85. The revenue growth (YoY) is -58.8%, while earnings growth (YoY) is not available due to the negative net income figure. The company's current ratio is a relatively high 7.86, indicating sufficient liquidity to meet short-term obligations.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $181.00M
- P/E Ratio
- N/A
- 52-Week High
- $24.17
- 52-Week Low
- $5.85
- Avg Volume
- 1.27M
- Beta
- 2.24
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 174